Search

Your search keyword '"Zhong, Lai-Ping"' showing total 338 results
Start Over Author "Zhong, Lai-Ping"
338 results on '"Zhong, Lai-Ping"'

1. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

Author

Lacas, Benjamin, Carmel, Alexandra, Landais, Cécile, Wong, Stuart J, Licitra, Lisa, Tobias, Jeffrey S, Burtness, Barbara, Ghi, Maria Grazia, Cohen, Ezra EW, Grau, Cai, Wolf, Gregory, Hitt, Ricardo, Corvò, Renzo, Budach, Volker, Kumar, Shaleen, Laskar, Sarbani Ghosh, Mazeron, Jean-Jacques, Zhong, Lai-Ping, Dobrowsky, Werner, Ghadjar, Pirus, Fallai, Carlo, Zakotnik, Branko, Sharma, Atul, Bensadoun, René-Jean, Redda, Maria Grazia Ruo, Racadot, Séverine, Fountzilas, George, Brizel, David, Rovea, Paolo, Argiris, Athanassios, Nagy, Zoltán Takácsi, Lee, Ju-Whei, Fortpied, Catherine, Harris, Jonathan, Bourhis, Jean, Aupérin, Anne, Blanchard, Pierre, Pignon, Jean-Pierre, Group, MACH-NC Collaborative, Adelstein, DJ, Alfonsi, M, Belkacemi, Y, Bar-Ad, V, Bernier, J, Bratland, Å, Calais, G, Campbell, B, Caudell, J, Chabaud, S, Chamorey, E, Chaukar, D, Choi, KN, Choussy, O, Collette, L, Cruz, JJ, Dani, C, Dauzier, E, Forastiere, AA, Garaud, P, Gregoire, V, Hackshaw, A, Haddad, E, Haffty, BG, Hansen, A, Hayoz, S, Horiot, JC, Jeremic, B, Karrison, TG, Langendijk, JA, Lapeyre, M, Lartigau, E, Leong, T, Le, QT, Lee, PPY, Lewin, F, Lin, A, Lopes, A, Mehta, S, Moon, J, Moyal, E, Occéan, BV, Olmi, P, Orecchia, R, O'Sullivan, B, Overgaard, J, Petit, C, Quon, H, Sanguineti, G, Satar, T, Simes, J, Simon, C, Sire, C, Staar, S, Stromberger, C, Strojan, P, Temam, S, Thomson, D, Timochenko, A, Torri, V, and Tseroni, V

Subjects
Cancer, Clinical Trials and Supportive Activities, Rare Diseases, Clinical Research, 6.5 Radiotherapy and other non-invasive therapies, Evaluation of treatments and therapeutic interventions, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Chemotherapy, Adjuvant, Head and Neck Neoplasms, Humans, Induction Chemotherapy, Randomized Controlled Trials as Topic, Meta-analysis, Review, Individual Patient Data, Randomised Clinical Trials, Chemotherapy, Radiotherapy, Head and Neck Cancer, MACH-NC Collaborative Group, Other Physical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Background and purposeThe Meta-Analysis of Chemotherapy in squamous cell Head and Neck Cancer (MACH-NC) demonstrated that concomitant chemotherapy (CT) improved overall survival (OS) in patients without distant metastasis. We report the updated results.Materials and methodsPublished or unpublished randomized trials including patients with non-metastatic carcinoma randomized between 1965 and 2016 and comparing curative loco-regional treatment (LRT) to LRT + CT or adding another timing of CT to LRT + CT (main question), or comparing induction CT + radiotherapy to radiotherapy + concomitant (or alternating) CT (secondary question) were eligible. Individual patient data were collected and combined using a fixed-effect model. OS was the main endpoint.ResultsFor the main question, 101 trials (18951 patients, median follow-up of 6.5 years) were analyzed. For both questions, there were 16 new (2767 patients) and 11 updated trials. Around 90% of the patients had stage III or IV disease. Interaction between treatment effect on OS and the timing of CT was significant (p

Published
2021

5. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

Author

Adelstein, D.J., Agarwal, J., Alfonsi, M., Argiris, A., Aupérin, A., Bacigalupo, A., Bar-Ad, V., Bartelink, H., Beadle, B., Belkacemi, Y., Bensadoun, R.J., Bernier, J., Blanchard, P., Bourhis, J., Bratland, Å., Brizel, D., Budach, V., Budach, W., Burtness, B., Calais, G., Campbell, B., Caudell, J., Chabaud, S., Chamorey, E., Chaukar, D., Cheugoua-Zanetsie, M., Cho, K.H., Choussy, O., Cruz Hernandez, J.J., Denham, J.W., Dobrowsky, W., Dominello, M.M, Driessen, C.M.L., Fallai, C., Forastiere, A.A., Fortpied, C., Fountzilas, G., Garaud, P., Garden, A.S., Gery, B., Ghadjar, P., Ghi, M.G., Ghosh Laskar, S., Graff-Cailleaud, P., Grau, C., Gregoire, V., Hackshaw, A., Haddad, E, Haffty, B.G., Hansen, A., Hay, J.H., Hayoz, S., Horiot, J.C., Hitt, R., Jeremic, B., Johansen, J., Jones, C., Julieron, M., Kristensen, C.A., Kumar, S., Lacas, B., Langendijk, J.A., Lapeyre, M., Lartigau, E., Licitra, L., Le, Q.T., Lee, J.W., Lee, P., Lewin, F., Li, Y., Lopes, A., Lotayef, M., Maciejewski, B., Mazeron, J.J., Mehta, S., Michalski, W., Moon, J., Moon, S.H., Moyal, E., Nankivell, M., Nilsson, P., Olmi, P., Orecchia, R., O'Sullivan, B., Overgaard, J., Parmar, M.K.B., Petit, C., Pignon, J.P., Pointreau, Y., Posner, M.R., Poulsen, M.G., Quon, H., Racadot, S., Rosenthal, D.I., Rovea, P., Ruo Redda, M.G., Sanguineti, G., Shenouda, G., Simes, J., Sharma, A., Simon, C., Sire, C., Skladowski, K., Spencer, S., Staar, S., Strojan, P., Stromberger, C., Suwinski, R., Szutkowski, Z., Takácsi-Nagy, Z., Tao, Y.G., Temam, S., Thomson, D., Tobias, J.S., Torres-Saavedra, P., Torri, V., Tripcony, L., Trotti, A., Tseroni, V., van Herpen, C., van Tinteren, H., Vermorken, J., Viegas, C.M.P., Vokes, E.E., Waldron, J., Wernecke, K.D, Widder, J., Wolf, G.T., Wong, S.J., Wu, J.S., Yamazaki, H., Zaktonik, B., Zackrisson, B., Zhong, L.P., Petit, Claire, Lacas, Benjamin, Pignon, Jean-Pierre, Le, Quynh Thu, Grégoire, Vincent, Grau, Cai, Hackshaw, Allan, Zackrisson, Björn, Parmar, Mahesh K B, Lee, Ju-Whei, Ghi, Maria Grazia, Sanguineti, Giuseppe, Temam, Stéphane, Cheugoua-Zanetsie, Maurice, O'Sullivan, Brian, Posner, Marshall R, Vokes, Everett E, Cruz Hernandez, Juan J, Szutkowski, Zbigniew, Lartigau, Eric, Budach, Volker, Suwiński, Rafal, Poulsen, Michael, Kumar, Shaleen, Ghosh Laskar, Sarbani, Mazeron, Jean-Jacques, Jeremic, Branislav, Simes, John, Zhong, Lai-Ping, Overgaard, Jens, Fortpied, Catherine, Torres-Saavedra, Pedro, Bourhis, Jean, Aupérin, Anne, and Blanchard, Pierre

Published
2021
Full Text
View/download PDF

11. Supplementary Figure 3 from Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease

Author

Zhong, Lai-Ping, primary, Zhu, Dong-Wang, primary, William, William N., primary, Liu, Ying, primary, Ma, Jie, primary, Yang, Cheng-Zhe, primary, Yang, Xiao, primary, Wang, Li-Zhen, primary, Li, Jiang, primary, Myers, Jeffrey N., primary, Lee, J. Jack, primary, Zhang, Chen-Ping, primary, and Zhang, Zhi-Yuan, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 2 from Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease

Author

Zhong, Lai-Ping, primary, Zhu, Dong-Wang, primary, William, William N., primary, Liu, Ying, primary, Ma, Jie, primary, Yang, Cheng-Zhe, primary, Yang, Xiao, primary, Wang, Li-Zhen, primary, Li, Jiang, primary, Myers, Jeffrey N., primary, Lee, J. Jack, primary, Zhang, Chen-Ping, primary, and Zhang, Zhi-Yuan, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 4 from Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease

Author

Zhong, Lai-Ping, primary, Zhu, Dong-Wang, primary, William, William N., primary, Liu, Ying, primary, Ma, Jie, primary, Yang, Cheng-Zhe, primary, Yang, Xiao, primary, Wang, Li-Zhen, primary, Li, Jiang, primary, Myers, Jeffrey N., primary, Lee, J. Jack, primary, Zhang, Chen-Ping, primary, and Zhang, Zhi-Yuan, primary

Published
2023
Full Text
View/download PDF

14. Data from Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease

Author

Zhong, Lai-Ping, primary, Zhu, Dong-Wang, primary, William, William N., primary, Liu, Ying, primary, Ma, Jie, primary, Yang, Cheng-Zhe, primary, Yang, Xiao, primary, Wang, Li-Zhen, primary, Li, Jiang, primary, Myers, Jeffrey N., primary, Lee, J. Jack, primary, Zhang, Chen-Ping, primary, and Zhang, Zhi-Yuan, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Tables 1 - 5 from Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease

Author

Zhong, Lai-Ping, primary, Zhu, Dong-Wang, primary, William, William N., primary, Liu, Ying, primary, Ma, Jie, primary, Yang, Cheng-Zhe, primary, Yang, Xiao, primary, Wang, Li-Zhen, primary, Li, Jiang, primary, Myers, Jeffrey N., primary, Lee, J. Jack, primary, Zhang, Chen-Ping, primary, and Zhang, Zhi-Yuan, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 1 from Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease

Author

Zhong, Lai-Ping, primary, Zhu, Dong-Wang, primary, William, William N., primary, Liu, Ying, primary, Ma, Jie, primary, Yang, Cheng-Zhe, primary, Yang, Xiao, primary, Wang, Li-Zhen, primary, Li, Jiang, primary, Myers, Jeffrey N., primary, Lee, J. Jack, primary, Zhang, Chen-Ping, primary, and Zhang, Zhi-Yuan, primary

Published
2023
Full Text
View/download PDF

31. Neoadjuvant Immunochemotherapy for Locally Advanced Resectable Oral Squamous Cell Carcinoma: A Prospective Single-Arm Trial

Author

Huang, Ying-ying, primary, Sun, Jing-jing, additional, Li, Jun, additional, Zhu, Dong-wang, additional, Dong, Minjun, additional, Dou, Sheng-jin, additional, Tang, Yong, additional, Shi, Wen-tao, additional, Sun, Qi, additional, Zhao, Tong-chao, additional, Zhou, Zhi-hang, additional, Zhou, Xin-yu, additional, Liu, Ying, additional, Li, Jiang, additional, Zhu, Guo-pei, additional, Zhang, Ding, additional, Chen, Ya-nan, additional, Zhu, Qi, additional, Ju, Wu-tong, additional, and Zhong, Lai-ping, additional

Published
2022
Full Text
View/download PDF

32. Neoadjuvant chemo-free combination of camrelizumab and apatinib for locally advanced resectable oral squamous cell carcinoma – A pilot study

Author

Ju, Wu-tong, primary, Xia, Rong-hui, additional, Zhu, Dong-wang, additional, Dou, Sheng-jin, additional, Zhu, Guo-pei, additional, Dong, Min-jun, additional, Wang, Li-zhen, additional, Sun, Qi, additional, Zhao, Tong-chao, additional, Zhou, Zhi-hang, additional, Liang, Si-yuan, additional, Huang, Ying-ying, additional, Tang, Yong, additional, Wu, Si-cheng, additional, Xia, Jing, additional, Chen, Shiqing, additional, Bai, Yuezong, additional, Li, Jiang, additional, Zhu, Qi, additional, and Zhong, Lai-ping, additional

Published
2021
Full Text
View/download PDF

37. Targeting ERK combined with apatinib may be a promising therapeutic strategy for treating oral squamous cell carcinoma

Author

Zhao, Tong-Chao, Liang, Si-Yuan, Zhou, Zhi-Hang, Ju, Wu-Tong, Zhang, Zhi-Yuan, Zhu, Dong-Wang, and Zhong, Lai-Ping

Subjects
stomatognathic diseases, cardiovascular system, Original Article, respiratory system, circulatory and respiratory physiology
Abstract

Apatinib is an oral tyrosine kinase inhibitor that targets VEGFR2 signaling and shows potent antitumor effects in various cancers. In this study, we explored the efficacy of apatinib against oral squamous cell carcinoma (OSCC). The relationships between VEGFR2 protein expression and clinical variables were investigated in OSCC patients. OSCC tissues had higher VEGFR2 levels than paracancerous tissues. Compared to patients with low VEGFR2 expression, patients with high VEGFR2 expression had poorer overall survival (OS) and disease-free survival (DFS). Apatinib significantly induced G0/G1 phase arrest and apoptosis, inhibited cell growth and colony formation ability, and blocked autophagic flux by downregulating p-AKT and p-mTOR signaling via the VEGFR2/AKT/mTOR pathway in vitro. Moreover, the inhibition of ERK phosphorylation increased apatinib-induced apoptosis in vitro and in vivo. Apatinib synergized with SCH772984 to achieve a more significant suppression of tumor growth than individual treatment, suggesting the combination of apatinib and SCH772984 as a potent OSCC therapy.

Published
2021

38. Effects of insulin-like growth factor binding protein 3 on cell growth and tumorigenesis in oral squamous cell carcinoma

Author

Xu, Hong-Yuan, Zhu, Dong-Wang, Zhong, Lai-Ping, Zhang, Zhi-Yuan, Yang, Cheng-Zhe, Yang, Xiao, and Zhang, Peng

Subjects
tumorigenesis, Cancer Research, Oncology, oral squamous cell carcinoma (OSCC), Original Article, Radiology, Nuclear Medicine and imaging, Insulin-like growth factor binding protein 3 (IGFBP3), small interfering RNA
Abstract

Background This study was performed to investigate the effect of insulin-like growth factor binding protein 3 (IGFBP3) on the biological behavior of tumor cells and tumorigenesis of oral squamous cell carcinoma (OSCC). Methods OSCC HB96, CAL27, and Tca8113 cells were transfected with the following plasmids: siRNA-IGFBP3, pcDNA-0-IGFBP3, or siRNA-NC (negative control). The effect of aberrant IGFBP3 on cell viability, apoptosis, and colony formation was assessed. Quantitative real-time PCR (qRT-PCR) and western blot analysis were used to measure IGFBP3 mRNA and protein levels, respectively. HB96 and CAL27 cells were transfected with IGFBP3-expressing lentiviral plasmids and then transplanted into nude mice to monitor xenograft tumor formation. Results An optimal transfection efficiency was obtained with 50 pmol siRNA-IGFBP3. Transient silencing of IGFBP3 significantly reduced cell viability, and increased apoptosis in comparison with the non-targeting negative control (NC). Overexpressing IGFBP3 promoted cell viability. Additionally, in comparison with the NC group, both cell growth and colony formation were reduced, while apoptosis was elevated in stably transfected cells. Moreover, silencing IGFBP3 inhibited cell viability and tumor formation in nude mice after 3 weeks, and colony formation, diminished tumorigenesis in nude mice, but promoted cell apoptosis in OSCC cells. Conclusions Collectively, our study revealed a protumorigenic role for IGFBP3 in OSCC cancer cells, and demonstrated a potential mechanism for the dysregulation of IGFBP3 in cell growth. Therefore, IGFBP3 may be a potential therapeutic target for the treatment of OSCC.

Published
2019

42. Chemotherapy and radiotherapy in locally advanced head and neck cancer : an individual patient data network meta-analysis

Author

Petit, Claire, Lacas, Benjamin, Pignon, Jean-Pierre, Le, Quynh Thu, Grégoire, Vincent, Grau, Cai, Hackshaw, Allan, Zackrisson, Björn, Parmar, Mahesh K. B., Lee, Ju-Whei, Ghi, Maria Grazia, Sanguineti, Giuseppe, Temam, Stéphane, Cheugoua-Zanetsie, Maurice, O'Sullivan, Brian, Posner, Marshall R., Vokes, Everett E., Cruz Hernandez, Juan J., Szutkowski, Zbigniew, Lartigau, Eric, Budach, Volker, Suwiński, Rafal, Poulsen, Michael, Kumar, Shaleen, Ghosh Laskar, Sarbani, Mazeron, Jean-Jacques, Jeremic, Branislav, Simes, John, Zhong, Lai-Ping, Overgaard, Jens, Fortpied, Catherine, Torres-Saavedra, Pedro, Bourhis, Jean, Aupérin, Anne, Blanchard, Pierre, Petit, Claire, Lacas, Benjamin, Pignon, Jean-Pierre, Le, Quynh Thu, Grégoire, Vincent, Grau, Cai, Hackshaw, Allan, Zackrisson, Björn, Parmar, Mahesh K. B., Lee, Ju-Whei, Ghi, Maria Grazia, Sanguineti, Giuseppe, Temam, Stéphane, Cheugoua-Zanetsie, Maurice, O'Sullivan, Brian, Posner, Marshall R., Vokes, Everett E., Cruz Hernandez, Juan J., Szutkowski, Zbigniew, Lartigau, Eric, Budach, Volker, Suwiński, Rafal, Poulsen, Michael, Kumar, Shaleen, Ghosh Laskar, Sarbani, Mazeron, Jean-Jacques, Jeremic, Branislav, Simes, John, Zhong, Lai-Ping, Overgaard, Jens, Fortpied, Catherine, Torres-Saavedra, Pedro, Bourhis, Jean, Aupérin, Anne, and Blanchard, Pierre

Abstract

BACKGROUND: Randomised, controlled trials and meta-analyses have shown the survival benefit of concomitant chemoradiotherapy or hyperfractionated radiotherapy in the treatment of locally advanced head and neck cancer. However, the relative efficacy of these treatments is unknown. We aimed to determine whether one treatment was superior to the other. METHODS: We did a frequentist network meta-analysis based on individual patient data of meta-analyses evaluating the role of chemotherapy (Meta-Analysis of Chemotherapy in Head and Neck Cancer [MACH-NC]) and of altered fractionation radiotherapy (Meta-Analysis of Radiotherapy in Carcinomas of Head and Neck [MARCH]). Randomised, controlled trials that enrolled patients with non-metastatic head and neck squamous cell cancer between Jan 1, 1980, and Dec 31, 2016, were included. We used a two-step random-effects approach, and the log-rank test, stratified by trial to compare treatments, with locoregional therapy as the reference. Overall survival was the primary endpoint. The global Cochran Q statistic was used to assess homogeneity and consistency and P score to rank treatments (higher scores indicate more effective therapies). FINDINGS: 115 randomised, controlled trials, which enrolled patients between Jan 1, 1980, and April 30, 2012, yielded 154 comparisons (28 978 patients with 19 253 deaths and 20 579 progression events). Treatments were grouped into 16 modalities, for which 35 types of direct comparisons were available. Median follow-up based on all trials was 6·6 years (IQR 5·0-9·4). Hyperfractionated radiotherapy with concomitant chemotherapy (HFCRT) was ranked as the best treatment for overall survival (P score 97%; hazard ratio 0·63 [95% CI 0·51-0·77] compared with locoregional therapy). The hazard ratio of HFCRT compared with locoregional therapy with concomitant chemoradiotherapy with platinum-based chemotherapy (CLRTP) was 0·82 (95% CI 0·66-1·01) for overall survival. The superiority of HFCRT was robust to sensi

Published
2021
Full Text
View/download PDF

47. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

Author

Petit, Claire, primary, Lacas, Benjamin, additional, Pignon, Jean-Pierre, additional, Le, Quynh Thu, additional, Grégoire, Vincent, additional, Grau, Cai, additional, Hackshaw, Allan, additional, Zackrisson, Björn, additional, Parmar, Mahesh K B, additional, Lee, Ju-Whei, additional, Ghi, Maria Grazia, additional, Sanguineti, Giuseppe, additional, Temam, Stéphane, additional, Cheugoua-Zanetsie, Maurice, additional, O'Sullivan, Brian, additional, Posner, Marshall R, additional, Vokes, Everett E, additional, Cruz Hernandez, Juan J, additional, Szutkowski, Zbigniew, additional, Lartigau, Eric, additional, Budach, Volker, additional, Suwiński, Rafal, additional, Poulsen, Michael, additional, Kumar, Shaleen, additional, Ghosh Laskar, Sarbani, additional, Mazeron, Jean-Jacques, additional, Jeremic, Branislav, additional, Simes, John, additional, Zhong, Lai-Ping, additional, Overgaard, Jens, additional, Fortpied, Catherine, additional, Torres-Saavedra, Pedro, additional, Bourhis, Jean, additional, Aupérin, Anne, additional, Blanchard, Pierre, additional, Adelstein, D.J., additional, Agarwal, J., additional, Alfonsi, M., additional, Argiris, A., additional, Aupérin, A., additional, Bacigalupo, A., additional, Bar-Ad, V., additional, Bartelink, H., additional, Beadle, B., additional, Belkacemi, Y., additional, Bensadoun, R.J., additional, Bernier, J., additional, Blanchard, P., additional, Bourhis, J., additional, Bratland, Å., additional, Brizel, D., additional, Budach, V., additional, Budach, W., additional, Burtness, B., additional, Calais, G., additional, Campbell, B., additional, Caudell, J., additional, Chabaud, S., additional, Chamorey, E., additional, Chaukar, D., additional, Cheugoua-Zanetsie, M., additional, Cho, K.H., additional, Choussy, O., additional, Cruz Hernandez, J.J., additional, Denham, J.W., additional, Dobrowsky, W., additional, Dominello, M.M, additional, Driessen, C.M.L., additional, Fallai, C., additional, Forastiere, A.A., additional, Fortpied, C., additional, Fountzilas, G., additional, Garaud, P., additional, Garden, A.S., additional, Gery, B., additional, Ghadjar, P., additional, Ghi, M.G., additional, Ghosh Laskar, S., additional, Graff-Cailleaud, P., additional, Grau, C., additional, Gregoire, V., additional, Hackshaw, A., additional, Haddad, E, additional, Haffty, B.G., additional, Hansen, A., additional, Hay, J.H., additional, Hayoz, S., additional, Horiot, J.C., additional, Hitt, R., additional, Jeremic, B., additional, Johansen, J., additional, Jones, C., additional, Julieron, M., additional, Kristensen, C.A., additional, Kumar, S., additional, Lacas, B., additional, Langendijk, J.A., additional, Lapeyre, M., additional, Lartigau, E., additional, Licitra, L., additional, Le, Q.T., additional, Lee, J.W., additional, Lee, P., additional, Lewin, F., additional, Li, Y., additional, Lopes, A., additional, Lotayef, M., additional, Maciejewski, B., additional, Mazeron, J.J., additional, Mehta, S., additional, Michalski, W., additional, Moon, J., additional, Moon, S.H., additional, Moyal, E., additional, Nankivell, M., additional, Nilsson, P., additional, Olmi, P., additional, Orecchia, R., additional, O'Sullivan, B., additional, Overgaard, J., additional, Parmar, M.K.B., additional, Petit, C., additional, Pignon, J.P., additional, Pointreau, Y., additional, Posner, M.R., additional, Poulsen, M.G., additional, Quon, H., additional, Racadot, S., additional, Rosenthal, D.I., additional, Rovea, P., additional, Ruo Redda, M.G., additional, Sanguineti, G., additional, Shenouda, G., additional, Simes, J., additional, Sharma, A., additional, Simon, C., additional, Sire, C., additional, Skladowski, K., additional, Spencer, S., additional, Staar, S., additional, Strojan, P., additional, Stromberger, C., additional, Suwinski, R., additional, Szutkowski, Z., additional, Takácsi-Nagy, Z., additional, Tao, Y.G., additional, Temam, S., additional, Thomson, D., additional, Tobias, J.S., additional, Torres-Saavedra, P., additional, Torri, V., additional, Tripcony, L., additional, Trotti, A., additional, Tseroni, V., additional, van Herpen, C., additional, van Tinteren, H., additional, Vermorken, J., additional, Viegas, C.M.P., additional, Vokes, E.E., additional, Waldron, J., additional, Wernecke, K.D, additional, Widder, J., additional, Wolf, G.T., additional, Wong, S.J., additional, Wu, J.S., additional, Yamazaki, H., additional, Zaktonik, B., additional, Zackrisson, B., additional, and Zhong, L.P., additional

Published
2021
Full Text
View/download PDF

48. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

Author

Lacas, Benjamin, primary, Carmel, Alexandra, additional, Landais, Cécile, additional, Wong, Stuart J., additional, Licitra, Lisa, additional, Tobias, Jeffrey S., additional, Burtness, Barbara, additional, Ghi, Maria Grazia, additional, Cohen, Ezra E.W., additional, Grau, Cai, additional, Wolf, Gregory, additional, Hitt, Ricardo, additional, Corvò, Renzo, additional, Budach, Volker, additional, Kumar, Shaleen, additional, Laskar, Sarbani Ghosh, additional, Mazeron, Jean-Jacques, additional, Zhong, Lai-Ping, additional, Dobrowsky, Werner, additional, Ghadjar, Pirus, additional, Fallai, Carlo, additional, Zakotnik, Branko, additional, Sharma, Atul, additional, Bensadoun, René-Jean, additional, Ruo Redda, Maria Grazia, additional, Racadot, Séverine, additional, Fountzilas, George, additional, Brizel, David, additional, Rovea, Paolo, additional, Argiris, Athanassios, additional, Nagy, Zoltán Takácsi, additional, Lee, Ju-Whei, additional, Fortpied, Catherine, additional, Harris, Jonathan, additional, Bourhis, Jean, additional, Aupérin, Anne, additional, Blanchard, Pierre, additional, Pignon, Jean-Pierre, additional, Adelstein, D.J., additional, Alfonsi, M., additional, Belkacemi, Y., additional, Bar-Ad, V., additional, Bernier, J., additional, Bratland, Å., additional, Calais, G., additional, Campbell, B., additional, Caudell, J., additional, Chabaud, S., additional, Chamorey, E., additional, Chaukar, D., additional, Choi, K.N., additional, Choussy, O., additional, Collette, L., additional, Cruz, J.J., additional, Dani, C., additional, Dauzier, E., additional, Forastiere, A.A., additional, Garaud, P., additional, Gregoire, V., additional, Hackshaw, A., additional, Haddad, E., additional, Haffty, B.G., additional, Hansen, A., additional, Hayoz, S., additional, Horiot, J.C., additional, Jeremic, B., additional, Karrison, T.G., additional, Langendijk, J.A., additional, Lapeyre, M., additional, Lartigau, E., additional, Leong, T., additional, Le, Q.T., additional, Lee, P.P.Y., additional, Lewin, F., additional, Lin, A., additional, Lopes, A., additional, Mehta, S., additional, Moon, J., additional, Moyal, E., additional, Occéan, B.V., additional, Olmi, P., additional, Orecchia, R., additional, O'Sullivan, B., additional, Overgaard, J., additional, Petit, C., additional, Quon, H., additional, Sanguineti, G., additional, Satar, T., additional, Simes, J., additional, Simon, C., additional, Sire, C., additional, Staar, S., additional, Stromberger, C., additional, Strojan, P., additional, Temam, S., additional, Thomson, D., additional, Timochenko, A., additional, Torri, V., additional, Tseroni, V., additional, Vermorken, J., additional, Vokes, E.E., additional, Waldron, J., additional, Wernecke, K.D., additional, Widder, J., additional, and Zackrisson, B., additional

Published
2021
Full Text
View/download PDF

50. Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome

Author

Ju, Wu‐tong, primary, Liu, Ying, additional, Wang, Li‐zhen, additional, Li, Jiang, additional, Ren, Guo‐xing, additional, Sun, Jian, additional, Tu, Wen‐yong, additional, Hu, Yong‐jie, additional, Ji, Tong, additional, Yang, Wen‐jun, additional, Li, Jun, additional, He, Yue, additional, Wang, Yan‐an, additional, Zhang, Chen‐ping, additional, Zhong, Lai‐ping, additional, and Zhang, Zhi‐yuan, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results